within Pharmacolibrary.Drugs.ATC.N;

model N02CD05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0028333333333333335,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0037,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Eptinezumab is a humanized monoclonal antibody that targets calcitonin gene-related peptide (CGRP), which is involved in migraine pathophysiology. It is used as a preventive treatment for migraine in adults and is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters obtained from adult healthy volunteers and patients with migraine.</p><h4>References</h4><ol><li>Xue-Ning Li, Hong-Rong Xu, Ellen Cui, Kamilla Buchberg Petersen, Janka Ryding, Anders Ettrup, Jette Buch Ã˜stergaard, Frank Larsen,Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial.,Clinical drug investigation,2023<a href='https://pubmed.ncbi.nlm.nih.gov/37917246/'>https://pubmed.ncbi.nlm.nih.gov/37917246/</a></li><li>Johan Areberg, Monika Rosen, Annika Lindsten, Marianne Dragheim, Janka Ryding,Population pharmacokinetics of eptinezumab in paediatric patients with migraine and dose selection for phase 3 paediatric migraine studies.,Basic & clinical pharmacology & toxicology,2024<a href='https://pubmed.ncbi.nlm.nih.gov/39206528/'>https://pubmed.ncbi.nlm.nih.gov/39206528/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02CD05;
